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Abstract
Background: The cannabis extract nabiximols (Sativex®) effectively supresses withdrawal symptoms and cravings in
treatment resistant cannabis dependent individuals, who have high relapse rates following conventional withdrawal
treatments. This study examines the efficacy, safety and cost-effectiveness of longer-term nabiximols treatment for outpatient
cannabis dependent patients who have not responded to previous conventional treatment approaches.
Methods/Design: A phase III multi-site outpatient, randomised, double-blinded, placebo controlled parallel design,
comparing a 12-week course of nabiximols to placebo, with follow up at 24 weeks after enrolment.
Four specialist drug and alcohol outpatient clinics in New South Wales, Australia.
One hundred forty-two treatment seeking cannabis dependent adults, with no significant medical, psychiatric or other
substance use disorders.
Nabiximols is an oromucosal spray prescribed on a flexible dose regimen to a maximum daily dose of 32 sprays; 8 sprays
(total 21.6 mg tetrahydrocannabinol (THC) and 20 mg cannabidiol (CBD)) four times a day, or matching placebo, dispensed
weekly. All participants will receive six-sessions of individual cognitive behavioural therapy (CBT) and weekly clinical reviews.
Primary endpoints are use of non-prescribed cannabis (self-reported cannabis use days, urine toxicology), safety measures
(adverse events and abuse liability), and cost effectiveness (incremental cost effectiveness in achieving additional Quality
Adjusted Life Years). Secondary outcomes include, improvement in physical and mental health parameters, substance use
other than cannabis, cognitive functioning and patient satisfaction measures.
Discussion: This is the first outpatient community-based randomised controlled study of nabiximols as an agonist
replacement medication for treating cannabis dependence, targeting individuals who have not previously responded to
conventional treatment approaches. The study and treatment design is modelled upon an earlier study with this population
and more generally on other agonist replacement treatments (e.g. nicotine, opioids).
Trial registration: Australian and New Zealand Clinical Trial Registry: ACTRN12616000103460 (Registered 1st February 2016).
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Background
Approximately 183 million people aged 15-64 years, (3.8%)
of the global population currently use cannabis worldwide,
dwarfing the use of all other globally regulated substances
[1, 2] . In Australia, it is estimated that about 6.6 million
people aged 14 years or older have used cannabis at some
stage in their lives [3], compared with approximately 22.2
million in the USA [4, 5]. Close to 10.4% of adults in
Australia between the age of 14 and over have used canna-
bis in the past 12 months [6], of which approximately 10%
report dependent patterns of use, making it the most com-
mon illicit drug of dependence [7].
Cannabis dependence is associated with a range of
health problems including cognitive, psychiatric, cardio-
vascular and respiratory disorders [1, 7, 8], and consider-
able societal burden [9]. Cannabis ranks second of all
illicit drugs in hospital associated costs [10], is the pri-
mary drug of concern in 24% of Australian alcohol and
other drug treatment services (AODTS) [11], and is
identified as a problem drug for 55% of addiction-related
treatment episodes [11].
The effectiveness of existing treatments for canna-
bis use disorders is far from satisfactory but consist-
ent with many other addictive disorders. Reviews of
current ‘best practice’ psychosocial interventions (e.g.
cognitive behavioural therapy (CBT)) indicate that
around 80% of patients relapse within 1-6 months
[12]. Treatment of acute cannabis withdrawal is as-
sociated with similar relapse rates [13, 14]. More ef-
fective approaches are required for people seeking
treatment for cannabis use related problems, and as
with the treatment of other chronic addiction condi-
tions, there is particular interest in the development
of treatment approaches that combine medication
with psychosocial interventions [15]. Whilst the im-
portance of medication to support current best prac-
tice psychosocial interventions has been identified
[15], there are as yet no efficacious pharmacother-
apies for cannabis dependence [16]. Medication trials
for cannabis dependence are an emerging area of re-
search [17]. Most trials have either been laboratory
based or focused only on treating withdrawal symp-
toms during initial abstinence rather than longer
term relapse prevention [18]. Medicines tested for
withdrawal treatment – with limited efficacy include
antidepressants such as bupropion, [19] the mood
stabilizers divalproex [20] and lithium [14], the α2
−adrenergic agonist lofexidine [21] and the supple-
ment N-acetylcysteine (NAC) [22].
A promising alternative is agonist replacement (or sub-
stitution) cannabinoid pharmacotherapies, akin to opioid
or nicotine replacement treatment [23]. Studies of canna-
binoid agonist medications in withdrawal treatment indi-
cate successful amelioration of withdrawal symptoms. The
rationale for agonist medications in cannabis dependence
is that they provide a safer route of administration (than
smoking), should reduce unsanctioned drug use by pre-
venting withdrawal and reducing cravings [13], and at-
tenuate the acute effects of smoked cannabis [24, 25],
potentially facilitating greater engagement in psychosocial
interventions. Together, these anticipated effects should
provide those also receiving psycho-social interventions
and related support to make the necessary lifestyle
changes, and distance themselves from drug-related cues,
prior to tapering off agonist medication.
Dronabinol, an orally administered synthetic analogue
of THC, dose-dependently reduced withdrawal symp-
toms in the laboratory [20], and improved retention in
an outpatient setting [26, 27]. Nabilone, another syn-
thetic THC analogue was efficacious in laboratory exper-
iments, but is as yet untested in clinical settings [21]. A
double blind placebo-controlled RCT [13] of nabiximols,
an oromucosal spray with approximately equal parts of
the cannabinoids THC and CBD, demonstrated success-
ful suppression of withdrawal symptoms and cravings
during inpatient detoxification, with greater rates of
treatment completion than placebo. However, the high
rates of relapse from continuous abstinence following
discharge (over two thirds in both groups, but delayed in
the nabiximols group) indicate limited longer-term ben-
efits of a 6-day nabiximols regimen.
The high rate of relapse after acute medication-assisted
withdrawal highlights the need for longer-term outpatient
trials of cannabinoid replacement therapies [15, 16].
Only one RCT has examined longer-term cannabinoid
agonist replacement treatment. Levin and colleagues [28],
compared a 12-week outpatient course of dronabinol to pla-
cebo in 121 cannabis dependent treatment seekers. Although
dronabinol was well tolerated, had higher treatment reten-
tion and reduced withdrawal symptoms, there was no advan-
tage of dronabinol over placebo in achieving abstinence from
illicit cannabis, the primary end-point of the study.
The pharmacological profile of nabiximols may have
advantages over other available THC agonist medica-
tions. Nabiximols is approved in Australia and a number
of countries for symptomatic relief of moderate to severe
spasticity in multiple sclerosis. It is an oralmucosal spray
containing extracts from Cannabis sativa plants grown
under licence in the UK by the company GW Pharma-
ceuticals, containing 2.7 mg THC and 2.5 mg CBD per
0.1 ml spray, with small amounts (4 mg/ml) of other
plant-derived cannabinoids. The buccal route of admin-
istration provides a rapid onset of action and more
favourable pharmacokinetics than oral THC or dronabi-
nol [26], more closely mimicking smoked cannabis use.
The anxiolytic effects of CBD present in nabiximols may
also ameliorate cravings and anxiety associated with
dependent cannabis use and withdrawal.
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Two outpatient pilot studies have examined the po-
tential role of nabiximols as an agonist replacement
therapy for cannabis withdrawal [29, 30]. In a within-
subject placebo controlled randomised controlled trial
with 8 participants, high nabiximols doses (up to
108 mg THC/100 mg CBD daily) were well tolerated
and significantly reduced cannabis withdrawal symp-
toms in those achieving abstinence from illicit canna-
bis use [29]. The same research group have recently
reported positive clinical findings (78% abstinence) in
an open label 12 week course of treatment with
nabiximols (average daily dosage 77.5 mgTHC/ 71.7
mg CBD) and psychological treatment in four partici-
pants [30]. These studies highlight nabiximols poten-
tial as a longer term agonist replacement approach,
however, to date, no outpatient large scale rando-
mised controlled trial has examined the safety and ef-
ficacy of nabiximols as a substitution medication in
the management of cannabis dependence.
Study objectives
This study examines the efficacy, safety and cost-
effectiveness of nabiximols in the outpatient treatment
of cannabis dependent treatment seeking patients who
have not previously responded to conventional psycho-
social interventions. Specific study objectives are:
– Primary Objective 1: To examine the effects of
nabiximols vs. placebo on a range of cannabis
treatment efficacy outcomes, primarily, changes in
illicit cannabis use during treatment and effects on
retention in treatment.
– Primary Objective 2: To examine the adverse event
profile and abuse liability of nabiximols as a take
home treatment for cannabis use disorder.
– Primary Objective 3: To assess the costs and health
related quality of life (HRQoL) associated with
nabiximols treatment and the potential societal
savings (decreased health care, improved
productivity, and decreased criminal behaviours).
– Secondary objectives: To examine changes in health
related outcomes during outpatient treatment with
nabiximols, including a range of mental and physical
health dimensions, cognitive function, and
psychosocial functioning.
Methods
Study design
This project is a phase III multisite (four-sites) out-
patient randomised double-blind placebo controlled par-
allel design comparing a 12-week course of buccally
administered nabiximols to placebo (Fig. 1). Both groups
receive structured ‘best practice’ individual counselling
based on cognitive behavioural therapy principles,
regular case management and clinical reviews over the
course of the trial. Medications (nabiximols, placebo) are
dispensed on a weekly basis, and study medication is
discontinued in week 12 using tapering doses. Partici-
pants are followed up at week 24, 12 weeks after dis-
continuation of nabiximols/placebo treatment. All
participants are also followed-up for confidential re-
search interviews, (irrespective of completion of the
trial intervention) at baseline (week 0), weeks 4, 8, 12
and 24. Overview of study procedures and sequence
of events is provided in Table 1.
Regulatory and funding
The design complies with requirements of the Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
line [31, 32] (see Additional file 1 for SPIRIT CONSORT
checklist), and has received ethical clearance from the
Human Research Ethics Committee of South East
Sydney Local Health District (HREC/14/POWH/701),
with relevant local site specific approvals. The University
of Sydney is the study sponsor. A National Health and
Medical Research Council (NHMRC) of Australia
Project Grant (#1088902) supports the research costs of
the study. Health service costs are predominately sup-
ported by the participating NSW Health services. Study
medications (nabiximols, placebo) are provided free to
the study by GW Pharmaceuticals. The study is regis-
tered on the Australian New Zealand Clinical Trials
Registry (ACTRN12616000103460).
A Data Safety Monitoring Board (DSMB) comprising
of an independent statistician, a researcher with canna-
binoid expertise, and an addiction medicine specialist
with extensive expertise in clinical trials oversees the
study.
Sites
Four clinical sites across three Local Health Districts in
New South Wales, Australia were selected to host the
study based on their location, history of providing spe-
cialist treatment services for cannabis dependent users,
and capacity to participate and co-ordinate clinical re-
search activities. Two clinical sites are based in the
South East Sydney Local Health District (The Langton
Centre and St George Hospital), one in Hunter New
England Local Health District (Newcastle Community
Health Services) and one in Western Sydney Local
Health District (Centre for Addiction Medicine).
Participants
Sample size
Based on the primary outcome measure (efficacy, safety
and cost-effectiveness of nabiximols in outpatient treat-
ment of cannabis dependence), a total sample size of
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Fig. 1 Overview of study design
Table 1 Table of schedule of events
Study period
Screen Enrol Post-allocation Follow up
Timepoint* -t1 0 Wk
1
Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 Wk8 Wk9 Wk
10
Wk
11
Wk
12
Wk
13
Wk 24
Enrolment
Phone screen (Eligibility) X
Informed consent for medical screen X
Medical screen/assessment (Eligibility) X
Informed consent for main study
participation
X
Allocation X
Intervention
Medication [Nabiximols or placebo] dispensed X X X X X X X X X X X X X
Nursing clinical reviews X X X X X X X X X X X X X
Medical clinical reviews X X X X X
CBT sessions X X X X X X
Urine drug screen X X X X X X X X X X X X X X
Assessments
Research Interviews. Variables include:
Cannabis & other substance use (TLFB),
CWS, AEs, Aberrant medication behaviour
(mod ORBIT), SF-6D (QOL), WHO Health and
Performance Questionnaire: CT version,
SF-36 (Physical and Mental health), DASS-21,
PHQ-15, OTI: BPI, Crime, Satisfaction,
Test blind (week 12 only)
X X X X X
Clinical (Nursing/medical) Review variables:
AEs, Aberrant medication behaviour (weigh
bottles), ratings dose adequacy, ATOP &
BPRS at 4 week intervals, reason for study
termination Wk 24.
X X X X X X X X X X X X
Cognitive assessment. Variables include
Blood samples (pre/post cognitive testing),
Cognitive testing, Abuse liability (subjective
liking, strength, Physiological response)
X X X
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142 participants (71 per group) is required to achieve
around 22% abstinence rates at 12-weeks for the placebo
group (ascertained by average of previous drug adminis-
tered clinical trials) and approximately 44% abstinence
rates for the nabiximols group (based on clinical judge-
ment of double the rate of abstinence than placebo) with
80% power (two-tailed) and α = 0.05.
Eligibility criteria
Inclusion criteria are: (a) age 18 to 65 years; (b) meet
ICD-10 cannabis dependence criteria; (c) inability to stop
cannabis use in previous attempts, operationalised as
relapse to cannabis use within one month of a substantive
cessation attempt (including prior episodes of counselling,
medication, or withdrawal treatment aimed at abstaining
from cannabis use), and (d) being willing and able to
provide informed consent and follow study procedures,
including agreeing to not drive or operate heavy machin-
ery and females of child bearing potential agree to use
reliable contraception during the duration of the trial.
Exclusion criteria
Exclusion criteria for the study are: (a) presence of another
substance use disorder other than nicotine or caffeine (i.e.
alcohol, other illicit or prescription drug dependence,
including methadone or buprenorphine treatment for opi-
oid dependence); (b) severe medical (e.g. severe chronic
pain, severe hepatic, cardiovascular or renal impairment)
or psychiatric disorder (e.g. unstable schizophrenia, recent
drug-induced psychosis, severe mood disorder), assessed
at medical screen; (c) women who are pregnant, lactating
or planning to become pregnant; (d) concerns regarding
safe storage of medication; (e) not available for follow up
(e.g. expected travel or incarceration); (f) mandated by
court to attend treatment and maintain abstinence for a
substance use disorder; (g) history of epilepsy or recurrent
seizures; and (i) current active or recent (within past
month) treatment for cannabis use disorder.
Early termination criteria
Early termination criteria for the study include: (i) severe
adverse side effects or deteriorating physical or mental
health; (ii) violation of treatment centre rules and condi-
tions (e.g. violence towards staff or other patients); (iii)
non-compliance with trial protocol, including missing/
not returning medication for more than two consecutive
weeks or persistent refusal to participate in trial proce-
dures (such as, non-adherence with study medications,
counselling, clinical reviews, case management urine
drug screen, bloods, research interviews or monitoring).
Recruitment
The study is promoted via; (i) referrals from Drug & Al-
cohol treatment services; (ii) media advertising,
including local newspapers and postcard placements;
and (iii) online advertising through University of Sydney
website.
A three-step recruitment procedure is used for the
study. Interested individuals contact either the central
trial coordinator or site-specific researchers by tele-
phone, and are screened for potential eligibility. Infor-
mation collected at telephone screen relate to the
selection criteria, including demographics; recent canna-
bis and other substance use in past 28 days, Cannabis
Severity of Dependence Scale (SDS) score [33]; participa-
tion in treatment for substance use disorder in last
28 days; self-reported severe mental and physical health
conditions; prior quit attempts; willingness and ability to
participate in the study, including weekly clinic attend-
ance. If deemed broadly eligible at telephone screen, the
potential participant is invited to attend a detailed
medical assessment with a study medical officer at one
of the four sites, generally within 1-2 weeks of the tele-
phone screen.
The medical assessment is conducted by a study med-
ical officer (SMO) - an Addiction Medicine Specialist or
delegated senior addiction medicine trainee, and involves
a comprehensive clinical assessment examining patient
goals, substance use and treatment history, physical and
mental health, and psychosocial conditions. In addition
to the physical and mental state examinations, clinical
investigations, such as, urine drug screen for cannabis
and other substance use, urine β-hCG in women to
exclude pregnancy, and blood tests are carried out as
clinically indicated (e.g. Liver Function Tests if con-
cerned regarding hepatic function). The SMO completes
the eligibility checklist following the assessment, and if
the patient is eligible and interested in participating in
the study, they are referred to the study researcher at
each site.
The researcher then provides detailed verbal and writ-
ten study information, and obtains written informed
consent to participate in the study. Upon signing the
informed consent form, participants are enrolled into
the study.
Randomisation and blinding
An independent statistician created a randomisation
schedule, which was then given to the lead trial pharma-
cist at each site. Participants are blindly randomised in a
1:1 ratio between groups, using the variable 8-block ran-
domisation schedule of 80 codes per site to maintain
blinding. Stratification occurs at each of the four sites
(aiming for a 1:1 random allocation at each site). Ran-
domisation and group allocation happen after enrolment
(informed consent) and prior to Day 1 of the study, en-
abling study medications to be prepared by the study
pharmacist at each site. The randomisation schedule and
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nabiximols and placebo canisters are only identifiable to
trial pharmacists at each site, who themselves have no
contact with participants. All participants, clinicians and
researchers involved in service delivery, data collection
and analysis remain blinded to group allocation (active
or placebo) until the end of the study.
Clinical intervention
Study medications
Nabiximols is an oromucosal spray delivered through a
mechanically actuated pump, with each spray delivering
100 μL (2.7 mg THC and 2.5 mg CBD). The placebo
medication consists of an alcohol base and peppermint
oil flavouring present in the active nabiximols medica-
tion, but does not include any cannabinoids and plant-
based terpenoids. A previous study [13] demonstrated
the ability to maintain blind dosing of nabiximols versus
placebo in cannabis dependent patients in an inpatient
setting. All dispensed medication canisters are labelled
with the subjects’ name, trial site, week number, medica-
tion dose, expiry date and prescribing doctors’ name.
The proposed dosing regimen for nabiximols is based
upon experience from previous studies with cannabis
dependent patients [13, 29, 30], and the principles of
dose titration used in similar clinical paradigms (opioid
agonist replacement therapy). Nabiximols and placebo
doses are individually titrated by the SMO with each
participant to optimise clinical effect (reduce cravings
and withdrawal) and safety (avoidance of side effects,
such as intoxication). Doses are reviewed and titrated by
the clinician and the patient regularly (daily for first two
days of Week 1, then at weekly intervals). Day 1 dose is
two sprays (5.4 mg THC, 5.0 mg CBD) four times a day
(QID), days 2 and 3 maximum dose is four sprays (10.8 mg
THC, 10 mg CBD) QID. Thereafter, the maximum daily
doses during the ‘maintenance’ period (to end week 12)
are 32 sprays (86.4 mg THC, 80 mg CBD) per day divided
into four doses (21.6 mg THC, 20 mg CBD QID). These
nabiximols doses are considerably greater than those
conventionally used for treating other indications (e.g. a
daily maximum dose for multiple sclerosis is 32.4 mg
THC, 30 mg CBD), reflecting the high THC tolerance of
cannabis dependent individuals and the need for high
doses to effectively ameliorate withdrawal symptoms and
cravings. During week 13, participants have the option of
tapered reductions of their study medication at approxi-
mately 10-15% per day, in order to minimise any medica-
tion discontinuation effects (e.g. withdrawal).
Clinical reviews
Weekly clinical reviews with a nurse and/or SMO in-
clude: a Time Line Follow Back (TLFB) [34] of their use
of study medication, cannabis, nicotine, alcohol and
other drugs in the past week since last clinical review; a
review of any adverse events; separate participant and
clinician assessment of medication dose adequacy (using
a 5-point Likert scale e.g. 1 = ‘much too low’, 3 = ‘about
right’ to 5 = ‘much too high’); participant rating of can-
nabis withdrawal severity using Cannabis Withdrawal
Scale (CWS) [35], general physical and mental health
and psychosocial conditions, examination (including
blood pressure (BP), pulse rate (PR), evidence of intoxi-
cation or withdrawal, or other findings of note) and the
opportunity to address other issues identified by the par-
ticipant. In addition to weekly reviews conducted by
nursing staff (baseline, days 1 and 2, weeks 3, 5, 6, 7, 9,
10, and 11), the SMO reviews the participant at weeks 2,
4, 8 and 12, at which time they also formally assess any
adverse events reported since the last medical review
and complete the Australian Treatment Outcomes
Profile (ATOP) [36], a validated clinician-completed in-
strument that includes participant ratings of physical
and mental health and range of clinical risks, such as,
child protection, violence, homelessness) and the Brief
Psychiatric Rating Scale (BPRS) [37] to formally assesses
psychiatric symptoms that may occur with high dose
THC use [38]. The SMO assess whether the participant
is globally deteriorating and warrants study discontinu-
ation. See Table 1 for schedule of events.
Psychosocial intervention
In conjunction with receiving medication treatment,
participants are provided with a minimum of six struc-
tured counselling sessions based on cognitive behav-
ioural therapy (CBT) [39]. The CBT sessions use a range
of strategies and interventions, such as, understanding
cannabis and the patient, preparing the patient for
change and various strategies, ways to manage with-
drawal and relapse prevention. Participation in the coun-
selling program is encouraged, and all participants must
attend at least 2 sessions (an initial assessment and one
further follow up) in order to continue in the study. Par-
ticipants may negotiate additional counselling sessions
with the therapist beyond the 12-week intervention
period. Counsellors complete de-identified research
Clinical Record Forms (CRFs) after each session to iden-
tify themes or areas covered according to the CBT inter-
vention as a strategy to record adherence with the
counselling intervention.
Outcome and treatment process measures
Outcome measures for each of the study objectives are
described below, and summarised in Tables 1 and 2.
Objective 1
To examine cannabis treatment efficacy outcomes, in-
cluding changes in illicit cannabis use during treatment
and treatment retention.
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– Illicit cannabis use is quantified as self-reported
number of days of illicit cannabis use and average
daily amount of cannabis use in grams at the 4
weekly research interviews using modified Timeline
Followback [40] techniques. The primary end-point
is self-reported illicit cannabis use days during the
maintenance phase of treatment (weeks 1-12).
Objective measures of illicit cannabis use will be
determined from weekly urine collection with
quantitative analysis of urinary THC, THC-COOH,
CBD and other cannabinoids. 4-weekly point preva-
lence abstinence during maintenance phase (weeks
1-4, 5-8, 9-12), and post-treatment period (week 24)
will be ascertained by combining self-report data
from researcher interviews and urinalysis.
– Treatment retention (days in protocol treatment) are
recorded from clinical records. Participants who do
not attend for more than two consecutive weeks are
deemed to have dropped out of treatment, and the
last scheduled day of dosing is calculated as the end
of treatment date.
Objective 2
To examine the adverse event profile, and the abuse li-
ability of nabiximols as a take home treatment for can-
nabis use disorder.
– Adverse events are assessed and addressed during
clinical assessments with the study medical officer at 4-
weekly appointments. At the end of study participation,
the SMO records the severity of each AE (mild, moder-
ate, severe), the outcome (ongoing or resolved, with or
without treatment), and attribution to study medication.
– Abuse liability: Adherence to study medication is
estimated by participants returning their medication
canisters at the weekly clinical review and weighing
the amounts of medication used (equivalent to a pill
count). Aberrant medication behaviours (missed
doses, extra ‘unsanctioned’ doses, misuse or
diversion) are assessed by self-report at researcher
interviews using the modified ORBIT [41], a vali-
dated aberrant medication behaviours self-report in-
strument. In addition, a series of subjective
assessments of abuse liability using the Visual
Analogue Scale (VAS) [42], (0-100) of subjective lik-
ing, comparability to cannabis, strength of effect and
subjective physiological effects are conducted 4-
weekly at researcher interviews.
Objective 3
To assess the costs and health related quality of life
(HRQoL) associated with the provision of nabiximols for
treatment of resistant cannabis use disorder and the
potential societal savings (decreased health care, im-
proved productivity, and changes in criminal behaviors).
– Cost effectiveness: Consistent with other drug
treatment cost effectiveness evaluations [43–45], the
primary outcome is Quality Adjusted Life Years
(QALY) measured by the SF-6D [46], (at 4 weekly
research interviews) determined using area under
the curve analysis [47] for each individual. Resources
included are all clinical services provided as trial in-
terventions (see Treatment Process Measures
below), adverse event management, self-reported
health care utilization outside of the trial (hospital,
emergency department, primary care and other spe-
cialist health services) as well as self-reported par-
ticipation in criminal activity that will be costed
using unit costs (CPI adjusted if necessary) [48]. Lost
productivity and personal costs are collected by struc-
tured self-report (WHO Health and Performance
Questionnaire: Clinical Trials Version) [49]. The costs
will be summed and combined with the outcome
measure, and the incremental cost-effectiveness ratio
[ICER = (CNabiximols-CControl)/(ENabiximols-EControl)]
calculated.
Secondary objectives
To examine changes in health-related outcomes during
outpatient treatment with nabiximols, including mental
and physical health, cognitive performance, and psycho-
social functioning
– Other substance use (alcohol, opioids, stimulants,
benzodiazepines, tobacco) are recorded by self-
report number of days used in the past 28 days using
the ATOP at 4-week research interview.
– Health outcomes and psychosocial function. The SF-
36 [50] is administered at 4-week research interviews
to assess dimensions of physical and mental health
and psychosocial function. Mental health will be also
be assessed using the Depression, Anxiety and Stress
Scale (DASS-21) [51] at 4-weekly research interviews
and the BPRS at 4-weekly medical reviews. Patient
reported ratings of physical health are also assessed
using the Physical Health Questionnaire-15 (PHQ-
15) [52]. Pain severity and pain interference is
assessed using the Brief Pain Inventory [53]. Subject-
ive sleep ratings are assessed using the Insomnia
Sleep Inventory [54]. Self-reported drug related
crime (e.g. drug dealing, income generating crime)
are examined using the Crime Section of the Opiate
Treatment Index [55].
– Cognitive function is assessed by the researcher at
baseline (week 0, day 1), during the maintenance
phase (week 4), and at follow-up (week 24). A
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targeted series of computerised tests sensitive to
acute THC effects are conducted, specifically an
acute battery: Eriksen Flanker Task [56], Stop Signal
Task [57], N-Back [58], Digit-Symbol Substitution
[59], and Rapid Visual Information Processing [60]
as well as a control measure (Wechsler Test of Adult
Reading [61]) and a measure of memory and learn-
ing (Ray Auditory Verbal Learning Test, RAVLT
[62]). At week 4 assessments, cognitive testing (acute
battery) are performed 30 min prior to (trough) and
45-60 min after (peak effects) supervised dosing.
Blood samples at trough and peak are taken for
plasma cannabinoid levels (THC, 11-OH THC,
THC-COOH, CBD, 11-OH CBD) to assist in the in-
terpretation of findings. The acute battery uses com-
puterised tests within the Penscreen system [63] that
create random numbers for stimuli to minimise
learning effects. Similarly, repeated memory assess-
ment use parallel versions of the RAVLT. It will be
of particular interest to examine whether nabiximols
is associated with cognitive improvement relative to
Placebo and relative to baseline. Week 24 cognitive
performance assessment is examined to investigate
within-subject longitudinal changes over time.
– Patient reported outcome and satisfaction measures:
Many of the study outcomes use ‘patient reported
outcome measures’ of specific domains. The Patient
Global Impression of Change Scale (PGICS) [64]
examines the participant’s assessment of change in
their global condition at week 12 since entering
treatment in the trial. Participants are also asked
questions relating to their satisfaction of treatment
medication and dose and their likelihood of
recommending it to others.
Treatment ‘process’ measures
details regarding participation in trial interventions are
collected on paper clinical record forms (CRF) and in-
clude details regarding doses of trial medication used
(reported at weekly clinical reviews), participation in
medical, counselling and clinical review sessions as well
as reasons for study termination (completed protocol,
treatment drop-out, medical discharge, administrative
discharge, incarceration). At the completion of the
‘maintenance’ medication phase of the trial (week 12 re-
searcher interview), participants are asked to estimate
which medication group they were assigned as a means
of testing the blind.
Research procedures
Research interviews
The research assistant at each site conducts research in-
terviews at weeks 0 (baseline), 4, 8, 12 and week 24.
Details of the instruments and timing of administration
are shown in Table 2.
Urinalysis and blood pathology testing
Blood and urine samples are collected in accordance
with the National Statement on Ethical Conduct in
Human Research (2007). All blood and urine samples
are taken and stored de-identified using the patients
study ID code.
Urine drug screens are collected during the medical
screen and on day 1 of commencing the trial to confirm
cannabis use and check for other drug use other than
cannabis (prior to study medication being administered).
Subsequent urine samples are collected weekly at the
clinical review (and at week 24 research interview), and
stored at − 20 °C until the end of the trial, with results
not being available to the clinical or research staff until
the completion of all data collection. The urine samples
will enable cannabinoid metabolite profiles to be charted
through time, as a means to identify ongoing illicit can-
nabis use, using creatinine corrections [65].
Blood samples are taken from all participants at base-
line, week 4 (immediately before and after cognitive test-
ing) and week 24 to determine serum cannabinoid
(THC, 11-OH THC, THC-COOH, CBD, 7-OH CBD)
levels. 10mls of blood are collected at each time-point
and immediately centrifuged at 4 °C for 15 min at 1500
RPM and plasma pipetted into 4 × 1 ml aliquots, imme-
diately frozen at − 20 °C. A Shimadzu 8030 triple quad-
rupole mass spectrometer will be used to analyse serum
cannabinoids (LCMS; Shimadzu Corp, Kyoto, Japan).
Statistical analyses
Chi square and ANOVA tests will be performed to iden-
tify any baseline covariates that differ between groups.
Prior to carrying out primary and secondary analysis, the
percentage of missing values in the raw dataset and Lit-
tle’s MCAR test will be used to determine if multiple im-
putation of missing values is required (except for
missing urine where cannabis use will be assumed to
have taken place). The multiple imputation will be done
if the percentage of missing values exceeds 5%.
All analyses will use Intention-to-treat, which is de-
fined as any person who is randomised to one of the
study arms and receives at least one dose of study medi-
cations. Mixed Models for Repeated Measures (MMRM)
will compare groups on changes in outcome variables
(cannabis use and secondary outcomes) in the medica-
tion phase with the multiply imputed dataset, (assuming
that Little’s MCAR at Random test confirms the data to
be missing at random). In addition, we will perform a
sensitivity analysis based on only those with complete
data, and compare results to that from the MI dataset
analysis.
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Adverse Events will be analysed using chi-square. A
Cox proportional hazards model will compare retention
in treatment between study arms, controlling for poten-
tial confounds. The impact of the intervention on post-
medication outcomes will compare changes in cannabis
use outcomes at baseline and at follow up between
groups using MMRMs.
Family-wise error corrections will control for Type 1
errors where multiple comparisons are performed within
a particular analysis where post hoc contrasts are per-
formed to further explore interesting (significant) findings.
Study limitations
This study has a number of possible limitations. One
issue relates to retention in study protocol. Participation
in the study is voluntary, and study procedures span
24 weeks, including 13 weeks of study treatment inter-
ventions. The lengthy treatment duration in the study is
generally longer than conventional treatment of cannabis
dependence, and participants may be deterred from en-
tering the trial or prematurely terminate study participa-
tion, which in turn may have implications in assessing
effectiveness of treatment outcomes and research follow-
up. Similarly, individuals enrolling in a medication study
may have different levels of interest or commitment to
the CBT in the study, which may enhance heterogeneity
of outcomes.
The study uses a flexible dosing approach to medication.
Whilst a fixed regimen – or indeed a structured compari-
son of different doses (e.g. high or low) is often used in
many medication studies – experience from opioid agonist
clinical and research practice highlights the need to tailor
doses to individual requirements, reflecting differing
physiological tolerance, adverse event profiles and behav-
ioural characteristics of patients. Nevertheless, the differ-
ent doses used may increase heterogeneity of outcomes
and limit the ability to detect significant differences if
there is indeed a major dose effect.
Measures of illicit cannabis use during treatment are
the primary study outcome, with self-reported use (via
the TLFB) as the primary endpoint. Participants may
have a response bias and report inaccurate drug use to
both clinicians and researchers. Whilst objective assess-
ment of illicit cannabis use using urine drug screening
should enhance self-report validity, it remains to be seen
whether illicit cannabis use can be differentiated from
prescribed nabiximols use. Various toxicological ap-
proaches are being examined to validate the identifica-
tion of illicit cannabis use in nabiximols prescribed
patients (to be described elsewhere).
Conclusion
There is a need for more effective treatment approaches
for cannabis dependent patients who are unable to
discontinue their illicit use through psychosocial inter-
ventions alone. Longer-term agonist replacement treat-
ment approaches rather than acute withdrawal
management are likely to be more effective, with the
combination of THC:CBD nabiximols preparation being
potentially advantageous over synthetic THC analogues.
This is the first large-scale outpatient RCT of nabiximols
for this population, and has required the development of
clinical and research methods specific to agonist treat-
ment with a plant-derived cannabinoid formulation,
building upon clinical research models previously used
in opioid agonist treatment approaches.
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